Bandingkan Harga & Kinerja Japfa Comfeed Indonesia Tbk. (JPFA) vs Organon Pharma Indonesia Tbk. (SCPI)
Kinerja harga (24 Jam Terakhir)
Statistik utama
Statistik utama
Perbedaan Japfa Comfeed Indonesia Tbk. dan Organon Pharma Indonesia Tbk.: Japfa Comfeed Indonesia Tbk. diperdagangkan di Rp2.250 (kapitalisasi pasar 27,21 T, volume 24 jam 21,43 jt), sedangkan Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M). Perbedaan utamanya: Japfa Comfeed Indonesia Tbk. jauh lebih besar — sekitar 260,6× kapitalisasi pasar Organon Pharma Indonesia Tbk.. Mana yang lebih baik tergantung tujuan investasimu.
| JPFA | SCPI | |
|---|---|---|
Kapitalisasi Pasar | 27,21 T | 104,4 M |
Volume | 21,43 jt | — |
Lot | 214,28 rb | — |
Perputaran | 48,33 M | — |
Harga Rata-rata | 2.255,47 | — |
Nilai Transaksi | 48,33 M | — |
Harga Ekuilibrium Indikatif | 2.250 | — |
Volume Ekuilibrium Indikatif | 16,2 rb | — |
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Berita terkini
Berita terbaru kedua aset
Berita terkini
Berita terbaru kedua aset
Tentang Japfa Comfeed Indonesia Tbk.
PT Japfa Comfeed Indonesia Tbk (the Company) was established within the framework of the Foreign Capital Investment Law No. 1 year 1967 based on Notarial Deed No. 59 dated January 18, 1971 of Djojo Muljadi, S.H., public notary, as amended by Notarial Deed No. 60 dated Februari 15, 1972, of the same notary. Japfa is currently the second largest animal feed producer in Indonesia with an estimated market share of around 35% in the domestic poultry feed market. The company was originally involved in the production of copra extraction pellets
Selengkapnya di halaman JPFA →Tentang Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Selengkapnya di halaman SCPI →
